Implantica's RefluxStop™ makes an impact at the leading Annual European Foregut Society Meeting

Implantica Liechtenstein

for further information.

About RefluxStop™

RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Existing surgical procedures and devices are focused on the Lower Esophageal Sphincter (LES) with a principal assumption that the LES is weak and or improperly functioning thereby not closing properly. These methods encircle the food passageway to support the LES's closing sphincter and are commonly  associated with side effects such as swallowing difficulties, inability to belch and vomit and gas bloating. In contrast, the RefluxStop™ device addresses acid reflux without affecting the food passageway.

The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

Newsroom
https://www.implantica.com/media/media-kit

Community

https://ch.linkedin.com/company/implantica

https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart
VP Marketing & Advocacy

M: [phone]
[e-mail]  

The following files are available for download:

https://mb.cision.com/Main/19732/3875947/2430188.pdf

Implantica’s RefluxStop™ makes an impact at the leading Annual European Foregut Society Meeting

https://news.cision.com/implantica/i/implantica-efs-booth,c3239270

Implantica EFS Booth

https://news.cision.com/implantica/i/logo-transparent-1-8,c3239269

logo transparent 1 8

https://news.cision.com/implantica/i/refluxstop,c3239271

REFLUXSTOP

 

View original content:https://www.prnewswire.co.uk/news-releases/implanticas-refluxstop-makes-an-impact-at-the-leading-annual-european-foregut-society-meeting-301988665.html

@ prnewswire.co.uk